BioCentury
ARTICLE | Clinical News

Biosimilar bevacizumab: Phase III started

February 3, 2014 8:00 AM UTC

Amgen disclosed in its 4Q13 and 2013 earning that it began a double-blind, international Phase III trial comparing ABP 215 plus carboplatin and paclitaxel vs. carboplatin and paclitaxel plus Avastin bevacizumab in about 620 patients. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) and its Genentech Inc. unit market Avastin. Amgen is developing the biosimilar with Actavis plc (NYSE:ACT, Dublin, Ireland) as part of a 6-product biosimilar portfolio under a 2011 deal. ...